Le Lézard
Classified in: Covid-19 virus
Subject: ATY

Nextdoor Holdings, Inc. f/k/a Khosla Ventures Acquisition Co. II Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - KIND


NEW YORK, March 26, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Nextdoor Holdings, Inc. f/k/a Khosla Ventures Acquisition Co. II (NYSE: KIND).

Shareholders who purchased shares of KIND during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE:

https://securitiesclasslaw.com/securities/nextdoor-holdings-inc-f-k-a-khosla-ventures-acquisition-co-ii-loss-submission-form/?id=72592&from=4

CLASS PERIOD: July 6, 2021 to November 8, 2022

ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (a) Nextdoor's financial results prior to the November 2021 merger with Khosla Ventures Acquisition Co. II, had been temporarily inflated by the ephemeral effects of the COVID-19 pandemic, which had pulled forward demand for Nextdoor's platform and cannibalized future advertising revenue growth; (b) rather than being sustained, such growth trends had already begun reversing at the start of the class period; (c) Nextdoor's total addressable market was materially smaller than the 312 million households represented to investors; (d) by the start of the class period, Nextdoor's most important market ? the U.S. market ? was already substantially saturated, impairing the Company's ability to monetize users and increase its average revenue per weekly active user, or U.S. weekly active user metrics; (e) as a result of (a)-(d) above, Nextdoor's revenue guidance for fiscal year 2022 had no reasonable basis in fact and the Company was tracking tens of millions of dollars below the revenue trajectory provided to investors.

DEADLINE: April 29, 2024 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/nextdoor-holdings-inc-f-k-a-khosla-ventures-acquisition-co-ii-loss-submission-form/?id=72592&from=4

NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of KIND during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is April 29, 2024. There is no cost or obligation to you to participate in this case.

WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [email protected]
Phone: (646) 453-8903

SOURCE The Gross Law Firm


These press releases may also interest you

at 03:05
Skechers, The Comfort Technology Company®, has opened its first concept store in Brussels on its most famous shopping street, Rue Neuve. Together with its store on Antwerp's Meir and planned Bruges concept store opening in mid-May, the Company is...

at 03:01
SolarBank Corporation (Cboe CA: SUNN) ("SolarBank" or the "Company") is pleased to provide an update on its significant...

at 02:27
Market Overview The Global Biometric Technologies Market is expected to grow at a compound annual growth rate (CAGR) of around 12% between 2024 and 2031, from an estimated USD 38 billion in 2023 to approximately USD 120 billion by 2031. Our study...

at 02:05
Positive topline results from the DESTINY-Breast06 phase 3 trial showed that ENHERTU® (trastuzumab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard of...

at 00:00
Building on its commitment to identify strengths and gaps in the R&D pipeline for antivirals, the INTREPID Alliance, a consortium of innovative biopharmaceutical companies dedicated to accelerating antiviral treatments to help protect the world ahead...

28 avr 2024
Pomerantz LLP announces that a class action lawsuit has been filed against QuidelOrtho Corporation ("QuidelOrtho" or the "Company") . Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW),...



News published on and distributed by: